DNM3 Antibody

1. In glioma, elevated miR-221 expression is a biomarker for glioma. DNM3 is a target of miR-221 and RELA regulates miR-221 expression. PMID: 27837435
2. Genetic variability in DNM3 modifies age of onset for LRRK2 Gly2019Ser parkinsonism. PMID: 27692902
3. DNM3 may be involved in risk of obsessive-compulsive disorder. PMID: 27023174
4. Microdeletion of DNM3 harboring miR199 and miR214 is associated with skeletal abnormalities. PMID: 26333682
5. DNM3 attenuates the proliferation and induces apoptosis of gastric cancer cells. PMID: 26784388
6. Data show that the classical dynamin DNM1 and DNM3 genes reach their maximum expression levels (100% of maximal expression) in all normal central nervous system tissues studied. PMID: 24673776
7. Data indicate that dynamin 3 (DNM3) harbors MEIS1 binding sites and is associated with differences in mean platelet volume (MPV). PMID: 22972982
8. DNM3 not only participates in megakaryocyte progenitor amplification, but is also involved in cytoplasmic enlargement and the formation of the demarcation membrane system. PMID: 21671749
9. Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients. PMID: 20700106
10. dynamin-3 and the postsynaptic adaptor Homer positions the endocytic zones near the postsynaptic density PMID: 17880892
11. Upon comparison of PBMC and skin samples of Sezary syndrome versus mycosis fungoides, CDO1 and DNM3 were found upregulated only in Sezary syndrome. PMID: 18033314
12. Dynamin 3 participates in the growth and development of megakaryocytes. PMID: 19007685

Show More

Hide All

HGNC: 29125

OMIM: 611445

KEGG: hsa:26052

STRING: 9606.ENSP00000350876

UniGene: Hs.654775